FLNA — FILANA THERAPEUTICS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About FILANA THERAPEUTICS INC (FLNA)
FILANA THERAPEUTICS INC (FLNA) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Steve Cohen (Point72 Asset Management), valued at $593,166. Across recent filings, tracked investors recorded 3 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in FLNA
How many top investors track FLNA
A small number of top investors own this.
FLNA Ownership Composition
How FILANA THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.
- Other90.7%
- Hedge Funds9.3%
Tracked investors reporting FLNA
- Steve CohenMar 31, 2026Point72 Asset ManagementShares39.1KValue$66.1K% Portfolio0.00%
- Izzy EnglanderMar 31, 2026Millennium ManagementShares72.6KValue$122.7K% Portfolio0.00%
- Ken GriffinMar 31, 2026Citadel AdvisorsShares311.1KValue$525.8K% Portfolio0.00%
Recent activity
- $543.3KFeb 17, 2026
- New$593.2KFeb 17, 2026
- New$66.1KMay 15, 2026
Frequently asked questions
- How many institutional investors hold FLNA?
- 3 tracked institutional investors disclosed a position in FLNA (FILANA THERAPEUTICS INC) in their most recent 13F filing.
- Who is the largest institutional holder of FLNA?
- Steve Cohen, Point72 Asset Management, holds the largest disclosed position in FLNA, valued at $593,166.
- Did institutional ownership of FLNA increase or decrease?
- Across recent 13F filings, tracked investors recorded 3 new positions, 0 increased, 0 reduced, and 0 fully exited FLNA.
- Where does this FLNA ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.